Clinical Trials Browser

Hepatic Impairment × tazemetostat × 90 days × Clear all

NCT04241835 2026-04-16

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Phase 1 Terminated

Other solid neoplasm

Hepatic Impairment